Amide based insulin prodrugs
US8697632B2 · kind B2 · utility
0Cited by
15References
27Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 18, 2009 |
| Grant date | Apr 15, 2014 |
| Priority date | — |
| Expiry date | Dec 18, 2029 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K14/625
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Prodrug formulations of insulin and insulin analogs are provided wherein the insulin peptide has been modified by an amide bond linkage of a dipeptide prodrug element. The prodrugs disclosed herein have extended half lives of at least 10 hours, and more typically greater than 2 hours, 20 hours and less than 70 hours, and are converted to the active form at physiological conditions through a non-enzymatic reaction driven by chemical instability.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.